skip to main content
Idioma:
Refinado por: Nome da Publicação: The Lancet remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

Franz, David Neal, Prof ; Belousova, Elena, MD ; Sparagana, Steven, MD ; Bebin, E Martina, MD ; Frost, Michael, MD ; Kuperman, Rachel, MD ; Witt, Olaf, MD ; Kohrman, Michael H, MD ; Flamini, J Robert, MD ; Wu, Joyce Y, MD ; Curatolo, Paolo, Prof ; de Vries, Petrus J, Prof ; Whittemore, Vicky H, PhD ; Thiele, Elizabeth A, MD ; Ford, James P, MS ; Shah, Gaurav, MD ; Cauwel, Helene, MSc ; Lebwohl, David, MD ; Sahmoud, Tarek, MD ; Jozwiak, Sergiusz, MD

The Lancet (British edition), 2013-01, Vol.381 (9861), p.125-132 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

Bissler, John J, Prof ; Kingswood, J Christopher, FRCP ; Radzikowska, Elżbieta, MD ; Zonnenberg, Bernard A, MD ; Frost, Michael, MD ; Belousova, Elena, Prof ; Sauter, Matthias, MD ; Nonomura, Norio, Prof ; Brakemeier, Susanne, MD ; de Vries, Petrus J, Prof ; Whittemore, Vicky H, PhD ; Chen, David, PhD ; Sahmoud, Tarek, MD ; Shah, Gaurav, MD ; Lincy, Jeremie, MS ; Lebwohl, David, MD ; Budde, Klemens, Prof

The Lancet (British edition), 2013-03, Vol.381 (9869), p.817-824 [Periódico revisado por pares]

Kidlington: Elsevier

Texto completo disponível

Citações Citado por
3
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Pavel, Marianne E, Prof ; Hainsworth, John D, Prof ; Baudin, Eric, MD ; Peeters, Marc, Prof ; Hörsch, Dieter, Prof ; Winkler, Robert E, MD ; Klimovsky, Judith, MD ; Lebwohl, David, MD ; Jehl, Valentine, MSc ; Wolin, Edward M, MD ; Öberg, Kjell, Prof ; Van Cutsem, Eric, Prof ; Yao, James C, Dr

The Lancet (British edition), 2011-12, Vol.378 (9808), p.2005-2012 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Motzer, Robert J, Dr, Prof ; Escudier, Bernard, MD ; Oudard, Stéphane, Prof ; Hutson, Thomas E, Prof ; Porta, Camillo, MD ; Bracarda, Sergio, MD ; Grünwald, Viktor, Prof ; Thompson, John A, Prof ; Figlin, Robert A, Prof ; Hollaender, Norbert, PhD ; Urbanowitz, Gladys, BS ; Berg, William J, MD ; Kay, Andrea, MD ; Lebwohl, David, MD ; Ravaud, Alain, Prof

The Lancet (British edition), 2008-08, Vol.372 (9637), p.449-456 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Griffiths, Christopher E M, Prof ; Reich, Kristian, Prof ; Lebwohl, Mark, Prof ; van de Kerkhof, Peter, Prof ; Paul, Carle, Prof ; Menter, Alan, MD ; Cameron, Gregory S, PhD ; Erickson, Janelle, PhD ; Zhang, Lu, MS ; Secrest, Roberta J, PhD ; Ball, Susan, PhD ; Braun, Daniel K, MD ; Osuntokun, Olawale O, MD ; Heffernan, Michael P, MD ; Nickoloff, Brian J, MD ; Papp, Kim, MD

The Lancet (British edition), 2015-08, Vol.386 (9993), p.541-551 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.